potential COVID-19 treatments - versus antiviral and associated therapy - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.96 [0.61, 1.51]< 10%4 studies (4/-)56.8 %some concernnot evaluable moderatecrucial-
clinical improvement 1.67 [0.35, 7.98]> 192%2 studies (2/-)73.8 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.53 [1.02, 2.29]> 10%1 study (1/-)98.0 %NAnot evaluable important-
clinical improvement (7-day) 1.46 [0.95, 2.23]> 10%1 study (1/-)95.8 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.15 [0.70, 1.87]> 184%3 studies (3/-)70.9 %some concernnot evaluable moderateimportant-
mechanical ventilation 1.62 [0.85, 3.08]< 10%1 study (1/-)7.2 %NAnot evaluable important-
radiologic improvement (7-day) 19.00 [0.85, 422.73]> 10%1 study (1/-)96.7 %NAnot evaluable important-
viral clearance 5.99 [1.51, 23.70]> 123%2 studies (2/-)99.5 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 4.37 [1.86, 10.25]> 10%1 study (1/-)100.0 %NAnot evaluable important-
viral clearance by day 14 1.84 [0.40, 8.38]> 10%1 study (1/-)78.4 %NAnot evaluable important-
viral clearance by day 7 3.93 [0.17, 89.94]> 174%2 studies (2/-)80.1 %some concernnot evaluable moderateimportant-
ICU admission 1.23 [0.70, 2.18]< 10%1 study (1/-)23.7 %NAnot evaluable non important-
recovery 0.81 [0.64, 1.03]> 10%1 study (1/-)4.4 %NAnot evaluable non important-
severe COVID-19 occurrence 0.30 [0.07, 1.27]< 10%1 study (1/-)94.9 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.43 [0.03, 5.81]< 10%2 studies (2/-)73.6 %some concernnot evaluable moderateimportant-
adverse events 0.12 [0.01, 2.86]< 10%1 study (1/-)90.1 %NAnot evaluable non important-
serious adverse events (SAE), any 0.50 [0.32, 0.79]< 10%1 study (1/-)99.9 %NAnot evaluable non important-

AE of interest endpoints 00

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.